NASDAQ · Biotechnology

Dyadic International, Inc. (DYAI) Stock

$0.44 -0.07% NASDAQ: DYAI Healthcare

Valuation

MetricValue
Price$0.44
Market Cap$16.18M
P/E Ratio-2.14
P/B Ratio-6.97
P/S Ratio4.79
EPS (TTM)$-0.23
52-Week High$1.60
52-Week Low$0.34
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-700.00%
ROA-116.60%
ROCE-279.48%
Gross Margin-700.00%
Operating Margin-700.00%
Net Margin-219.50%
Debt/Equity-2.11
Current Ratio2.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$2.0M$3.0M$3.0M$3.0M$1.0M
Operating Profit$-15.0M$-10.0M$-8.0M$-6.0M$-7.0M
Net Profit$-13.0M$-10.0M$-7.0M$-6.0M$-7.0M
EPS$-0.47$-0.34$-0.24$-0.20$-0.23
Op Margin-612.7%-346.9%-283.9%-168.8%-579.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$21.0M$14.0M$8.0M$10.0M$10.0M
Total Liabilities$3.0M$3.0M$2.0M$7.0M$9.0M
Cash$16.0M$6.0M$7.0M$7.0M$5.0M
Borrowings$0$0$0$5.0M$5.0M

Latest News

Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program GlobeNewswire · Jul 16, 2026 Dyadic International Progresses Multiple Protein Production Partnerships MT Newswires · Jul 7, 2026 Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential GlobeNewswire · Jul 7, 2026 Dyadic International Receives Japan Patent Allowance for Recombinant Protein Expression Technology MT Newswires · Jun 29, 2026 Dyadic Expands IP Protection and Business Development Activities in Japan GlobeNewswire · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-11.0M$-8.0M$-7.0M$-4.0M$-6.0M
Investing Cash Flow$5.0M$-2.0M$7.0M$-2.0M$0
Financing Cash Flow$1.0M$1.0M$0$0$0
Net Cash Flow$-5.0M$-10.0M$1.0M$0$-1.0M
Free Cash Flow$-11.0M$-8.0M$-7.0M$-4.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.13
EV / EBITDA-2.82
FCF Yield-44.51%
Quick Ratio1.65
Interest Coverage-17.71
Return 1Y22.45%
Return 3Y-35.83%
Return 5Y-64.71%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANVSAnnovis Bio, Inc. $1.21 +3.42% -0.67 $51.48M 0.00%
ATHEAlterity Therapeutics Limited $4.70 -5.62% -6.89 $42.60M 0.00%
BCAB $1.74 +0.00% -0.12 $2.88M 0.00%
CELUCelularity Inc. $1.56 +6.85% -0.51 $45.16M 0.00%
ELUTElutia, Inc. $0.82 -0.51% 0.60 $36.39M 0.00%

About Dyadic International, Inc.

Dyadic International, Inc. is led by CEO Mark A. Emalfarb, employs 6 people, headquartered in US, publicly traded since 2008.

Dyadic International, Inc. (DYAI) stock trades at $0.44 with a market capitalization of $16.18M. The stock is valued at a price-to-earnings (P/E) ratio of -2.14, price-to-book of -6.97, price-to-sales of 4.79. Over the past 52 weeks the stock has ranged between $0.34 and $1.60, and currently trades 72.5% below its 52-week high.

On profitability, Dyadic International, Inc. generates a return on equity (ROE) of -700.00%, return on capital employed of -279.48%, an operating margin of -700.00%, a net profit margin of -219.50%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides